Although there have been research on the efficacy of rAD-p53 therapy for the treatment of HNSCC [21,22,23], the emphasis of this systematic review is on assessing the clinical benefits of using rAD-p53 gene therapy for oral leukoplakia and OSCC as a stand-alone or in combination with other treatments. Here, TP53 is linked to head and neck squamous cell carcinoma.